Page 79 - 51 the significance--29.2_opt

103. Courreges JP, Vilsboll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, et al. Beneficial
effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on
cardiovascular risk biomarkers in patients with Type 2 diabetes. Diabet Med 2008;
25(9):1129-31.
104. Olansky L. Do incretin-based therapies cause acute pancreatitis? J Diabetes Sci
Technol 2010;4(1):228-29.
105. Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M. (R)-8-(3-
amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazoli n-2-ylmethyl)-3,7-
dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4
inhibitor, has a superior potency and longer duration of action compared with
other dipeptidyl peptidase-4 inhibitors. The Journal of pharmacology and experi-
mental therapeutics 2008;325(1):175-82.
106. Biftu T, Feng D, Qian X, Liang GB, Kieczykowski G, Eiermann G, et al. (3R)-4-[(3R)-3-
Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoro ethyl)-1,4-diazepan-2-one,
a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Bioorg Med Chem Lett 2007;17(1):49-52.
107. Brandt I, Joossens J, Chen X, Maes MB, Scharpe S, De Meester I, et al. Inhibition
of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-
hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile). Biochem Pharma-
col 2005;70(1):134-43.
108. Deacon CF, Holst JJ. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the
treatment of type 2 diabetes. Advances in therapy 2009;26(5):488-99.
109. Feng J, Zhang Z, Wallace MB, Stafford JA, Kaldor SW, Kassel DB, et al. Discovery of
alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl
peptidase IV. Journal of medicinal chemistry 2007;50(10):2297-300.
110. Matsuyama-Yokono A, Tahara A, Nakano R, Someya Y, Nagase I, Hayakawa M, et
al. ASP8497 is a novel selective and competitive dipeptidyl peptidase-IV inhibitor
with antihyperglycemic activity. Biochem Pharmacol 2008;76(1):98-107.
111. Kirby M, Yu DM, O’Connor S, Gorrell MD. Inhibitor selectivity in the clinical application
of dipeptidyl peptidase-4 inhibition. Clin Sci (Lond);118(1):31-41.
112. Heise T, Graefe-Mody EU, Huttner S, Ring A, Trommeshauser D, Dugi KA. Pharma-
cokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin,
a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes, obesity
& metabolism 2009;11(8):786-94.
113. Baseline HbA1c: 8.0% linagliptin-treated group; 8.0% placebo group; Full analysis
set (FAS), Last observation carried forward (LOCF). ADA 70th Scientific Sessions;
2010; Orlando, Florida, USA.
114. Baseline HbA1c: 8.09% linagliptin-treated group; 8.02% placebo group; full analysis
set (FAS), Last observation carried forward (LOCF) ADA 70th Scientific Sessions;
2010; Orlando, Florida, USA.
115. Linagliptin monotherapy improves glycaemic control and measures of beta-cell
function in Type 2 diabetes. ADA 70th Scientific Sessions; 2010; Orlando, Florida,
USA.
116. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone
in patients with inadequately controlled Type 2 diabetes. ADA 70th Scientific Sessions;
2010; Orlando, Florida, USA.
117. Kawamori R, Inagaki N, Araki E, Watada H, Hayashi N, Horie Y, et al. Linagliptin
monotherapy provides superior glycaemic control versus placebo or voglibose with
comparable safety in Japanese patients with type 2 diabetes: a randomized,
placebo and active comparator-controlled, double-blind study. Diabetes, obesity
& metabolism 2011.
118. Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA. Effect of
linagliptin monotherapy on glycaemic control and markers of beta-cell function in
patients with inadequately controlled type 2 diabetes: a randomized controlled
trial. Diabetes, obesity & metabolism 2011;13(3):258-67.
119. Taskinen MR, Rosenstock J, Tamminen I, Kubiak R, Patel S, Dugi KA, et al. Safety and
efficacy of linagliptin as add-on therapy to metformin in patients with type 2
diabetes: a randomized, double-blind, placebo-controlled study. Diabetes, obesity
& metabolism 2011;13(1):65-74.
120. Owens DR, Swallow R, Dugi KA, Woerle HJ. Efficacy and safety of linagliptin in persons
with type 2 diabetes inadequately controlled by a combination of metformin and
sulphonylurea: a 24-week randomized study. Diabet Med 2011;28(11):1352-61.

79